← Other lipid agents × cardiovascular events

Observational studyEuropean heart journal. Cardiovascular pharmacotherapy2025

Fenofibrate therapy and risk of heart failure outcomes in patients with Type 2 diabetes: a propensity-matched cohort study.

Ji Yoon Kim et al.PubMed ↗Full text ↗Publisher ↗

Statin plus fenofibratelooks good hereLower hospitalization for HF, fewer composite outcome of HHF or cardiovascular deaths.Weak evidence: one subgroup.

What the trial testedrandomised · 22 people · 2025

One subgroup

May have lowered hospitalization for HF in individuals with ≥80% adherence

−37%−57% to −8%

statin plus fenofibrate vs statin only, in individuals with ≥80% adherence

Bigger than 8 in 10 for cardiovascular events

As reported

HR 0.63, 95% CI 0.43–0.92

One subgroup

May have reduced composite outcome of HHF or cardiovascular deaths in individuals with ≥80% adherence

−32%−52% to −3%

statin plus fenofibrate vs statin only, in individuals with ≥80% adherence

Bigger than 7 in 10 for cardiovascular events

As reported

HR 0.68, 95% CI 0.48–0.97 · the paper's word: composite outcome of HHF or cardiovascular death

Not counted

Probably lowered hospitalization for HF

−20%−35% to −2%

statin plus fenofibrate vs statin only

Bigger than 4 in 10 for cardiovascular events

As reported

HR 0.80, 95% CI 0.65–0.98

Not counted

Probably reduced composite outcome of HHF or cardiovascular deaths

−21%−35% to −4%

statin plus fenofibrate vs statin only

Bigger than 5 in 10 for cardiovascular events

As reported

HR 0.79, 95% CI 0.65–0.96 · the paper's word: composite outcome of HHF or cardiovascular death

Who was studied, and how

22people with type 2 diabetes, in this paper

The trial randomly assignedassigned by chance

statin plus fenofibrate

statin only

Probably lowered hospitalization for HF−20%

Probably reduced composite outcome of HHF or cardiovascular deaths−21%

randomised

Among individuals with ≥80% adherence, the trial randomly assignedassigned by chance

statin plus fenofibrate

statin only

May have lowered hospitalization for HF−37%

May have reduced composite outcome of HHF or cardiovascular deaths−32%

randomised · one subgroup

the abstract, start to end

… (adjusted hazard ratio [HR], 0.80; 95% confidence interval [CI], …

… of HHF or cardiovascular death was 0.79 (95% CI, 0.65-0.96).

… consistent results (HHF: adjusted HR, 0.63; 95% CI, 0.43-0.92; composite outcome: adjusted HR, 0.68; 95% CI, 0.48-0.97).

← favours treatmentfavours comparator →

could be chance

Hospitalization for HF (HHF)statin plus fenofibrate vs statin only

HR 0.800.65–0.98

Composite outcome of HHF or cardiovascular deathstatin plus fenofibrate vs statin only

HR 0.790.65–0.96

Hospitalization for HF (HHF)statin plus fenofibrate vs statin only, in individuals with ≥80% adherence

HR 0.630.43–0.92

Composite outcome of HHF or cardiovascular deathstatin plus fenofibrate vs statin only, in individuals with ≥80% adherence

HR 0.680.48–0.97

StatinsOther lipid agentsCardiovascular events

1 / 5

2 papers cite it

2025

2026

this paperpooled itcites it

Fenofibrate therapy and risk of heart failure outcomes in patients with Type 2 diabetes: a propensity-matched cohort study.

What the trial testedrandomised · 22 people · 2025

May have lowered hospitalization for HF in individuals with ≥80% adherence

May have reduced composite outcome of HHF or cardiovascular deaths in individuals with ≥80% adherence

Probably lowered hospitalization for HF

Probably reduced composite outcome of HHF or cardiovascular deaths

Who was studied, and how

Four numbers in the abstract

Where each one falls

Only readable comparisons vote

Where it lands on the map

2 papers cite it